Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015 (2015), Article ID 478753, 12 pages
http://dx.doi.org/10.1155/2015/478753
Research Article

TACI Expression and Signaling in Chronic Lymphocytic Leukemia

1Department of Immunology & Histocompatibility, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis 3, 41500 Larissa, Greece
2Department of Hematology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis 3, 41500 Larissa, Greece
3Fourth Department of Internal Medicine, Ippokration Hospital, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54642 Thessaloniki, Greece
4Department of Hematology, Papageorgiou General Hospital, Periferiaki Odos Thessalonikis, Nea Efkarpia, 56429 Thessaloniki, Greece

Received 20 November 2014; Accepted 15 March 2015

Academic Editor: Jacek Tabarkiewicz

Copyright © 2015 Antigoni Mamara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Chiorazzi, “Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells,” Best Practice and Research: Clinical Haematology, vol. 20, no. 3, pp. 399–413, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. N. E. Kay, T. J. Hamblin, D. F. Jelinek et al., “Chronic lymphocytic leukemia,” Hematology/American Society of Hematology Education Program, vol. 2002, pp. 193–213, 2002. View at Google Scholar
  3. T. J. Hamblin, Z. Davis, A. Gardiner, D. G. Oscier, and F. K. Stevenson, “Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia,” Blood, vol. 94, no. 6, pp. 1848–1854, 1999. View at Google Scholar · View at Scopus
  4. R. N. Damle, T. Wasil, F. Fais et al., “Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia,” Blood, vol. 94, no. 6, pp. 1840–1847, 1999. View at Google Scholar · View at Scopus
  5. H. Döhner, S. Stilgenbauer, A. Benner et al., “Genomic aberrations and survival in chronic lymphocytic leukemia,” The New England Journal of Medicine, vol. 343, no. 26 I, pp. 1910–1916, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Moreno and E. Montserrat, “Genetic lesions in chronic lymphocytic leukemia: what's ready for prime time use?” Haematologica, vol. 95, no. 1, pp. 12–15, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. T. Scupoli and G. Pizzolo, “Signaling pathways activated by the B-cell receptor in chronic lymphocytic leukemia,” Expert Review of Hematology, vol. 5, no. 3, pp. 341–348, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Oppezzo and G. Dighiero, “Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia,” Blood Cancer Journal, vol. 3, article e149, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. A. J. Novak, R. J. Bram, N. E. Kay, and D. F. Jelinek, “Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival,” Blood, vol. 100, no. 8, pp. 2973–2979, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. B. He, A. Chadburn, E. Jou, E. J. Schattner, D. M. Knowles, and A. Cerutti, “Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL,” The Journal of Immunology, vol. 172, no. 5, pp. 3268–3279, 2004. View at Google Scholar
  11. C. Kern, J.-F. Cornuel, C. Billard et al., “Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway,” Blood, vol. 103, no. 2, pp. 679–688, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Nishio, T. Endo, N. Tsukada et al., “Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1α,” Blood, vol. 106, no. 3, pp. 1012–1020, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Endo, M. Nishio, T. Enzler et al., “BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway,” Blood, vol. 109, no. 2, pp. 703–710, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Cols, C. M. Barra, B. He et al., “Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L,” The Journal of Immunology, vol. 188, no. 12, pp. 6071–6083, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Yu, T. Boone, J. Delaney et al., “APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity,” Nature Immunology, vol. 1, no. 3, pp. 252–256, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. L. G. Ng, A. P. R. Sutherland, R. Newton et al., “B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells,” The Journal of Immunology, vol. 173, no. 2, pp. 807–817, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Mackay, P. Schneider, P. Rennert, and J. Browning, “BAFF and APRIL: a tutorial on B cell survival,” Annual Review of Immunology, vol. 21, pp. 231–264, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Pieper, B. Grimbacher, and H. Eibel, “B-cell biology and development,” The Journal of Allergy and Clinical Immunology, vol. 131, no. 4, pp. 959–971, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Bojarska-Junak, I. Hus, M. Sieklucka et al., “The role of TACI expression in chronic lymphocytic leukemia,” Central-European Journal of Immunology, vol. 36, no. 1, pp. 46–50, 2011. View at Google Scholar · View at Scopus
  20. J. Briones, J. M. Timmerman, D. M. Hilbert, and R. Levy, “BLyS and BLyS receptor expression in non-Hodgkin's lymphoma,” Experimental Hematology, vol. 30, no. 2, pp. 135–141, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. S. A. Mihalcik, R. C. Tschumper, and D. F. Jelinek, “Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies,” Cell Cycle, vol. 9, no. 24, pp. 4884–4892, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. S. S. Kim, K. A. Kirou, and D. Erkan, “Belimumab in systemic lupus erythematosus: an update for clinicians,” Therapeutic Advances in Chronic Disease, vol. 3, no. 1, pp. 11–23, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Fairfax, I. R. Mackay, and F. Mackay, “BAFF/BLyS inhibitors: a new prospect for treatment of systemic lupus erythematosus,” IUBMB Life, vol. 64, no. 7, pp. 595–602, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. S. M. Ansell, T. E. Witzig, D. J. Inwards et al., “Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma,” Clinical Cancer Research, vol. 14, no. 4, pp. 1105–1110, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. D. M. Kofler, B. B. Gawlik, T. Elter, A. Gianella-Borradori, C.-M. Wendtner, and M. Hallek, “Phase 1b trial of atacicept, a recombinant protein binding BLyS and APRIL, in patients with chronic lymphocytic leukemia,” Leukemia, vol. 26, no. 4, pp. 841–844, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Guadagnoli, F. C. Kimberley, U. Phan et al., “Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas,” Blood, vol. 117, no. 25, pp. 6856–6865, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Hojo, Y. Sasaki, N. Nakamura, and M. Abe, “Absence of somatic hypermutation of immunoglobulin heavy chain variable region genes in precursor B-lymphoblastic lymphoma: a study of four cases in childhood and adolescence,” American Journal of Clinical Pathology, vol. 116, no. 5, pp. 673–682, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. E. A. Ranheim, M. J. Cantwell, and T. J. Kipps, “Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells,” Blood, vol. 85, no. 12, pp. 3556–3565, 1995. View at Google Scholar · View at Scopus
  30. R. N. Damle, F. Ghiotto, A. Valetto et al., “B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes,” Blood, vol. 99, no. 11, pp. 4087–4093, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Argentou, G. Vassilopoulos, M. Ioannou, A. E. Germenis, and M. Speletas, “Rapid detection of MYD88-L265P mutation by PCR-RFLP in B-cell lymphoproliferative disorders,” Leukemia, vol. 28, no. 2, pp. 447–449, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Ghia, K. Stamatopoulos, C. Belessi et al., “Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene,” Blood, vol. 105, no. 4, pp. 1678–1685, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. J. R. Darce, B. K. Arendt, X. Wu, and D. F. Jelinek, “Regulated expression of BAFF-binding receptors during human B cell differentiation,” Journal of Immunology, vol. 179, no. 11, pp. 7276–7286, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. F. Malavasi, S. Deaglio, R. Damle, G. Cutrona, M. Ferrarini, and N. Chiorazzi, “CD38 and chronic lymphocytic leukemia: a decade later,” Blood, vol. 118, no. 13, pp. 3470–3478, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Kreuzaler, M. Rauch, U. Salzer et al., “Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors,” The Journal of Immunology, vol. 188, no. 1, pp. 497–503, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Planelles, S. Castillo-Gutiérrez, J. P. Medema, A. Morales-Luque, H. Merle-Béral, and M. Hahne, “APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival,” Haematologica, vol. 92, no. 9, pp. 1284–1285, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Bojarska-Junak, I. Hus, S. Chocholska et al., “BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features,” Leukemia Research, vol. 33, no. 10, pp. 1319–1327, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Haiat, C. Billard, C. Quiney, F. Ajchenbaum-Cymbalista, and J.-P. Kolb, “Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia,” Immunology, vol. 118, no. 3, pp. 281–292, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. U. Klein, Y. Tu, G. A. Stolovitzky et al., “Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells,” The Journal of Experimental Medicine, vol. 194, no. 11, pp. 1625–1638, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Rosenwald, A. A. Alizadeh, G. Widhopf et al., “Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia,” The Journal of Experimental Medicine, vol. 194, no. 11, pp. 1639–1647, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Seifert, L. Sellmann, J. Bloehdorn et al., “Cellular origin and pathophysiology of chronic lymphocytic leukemia,” The Journal of Experimental Medicine, vol. 209, no. 12, pp. 2183–2198, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. J. A. Burger, “Nurture versus nature: the microenvironment in chronic lymphocytic leukemia,” Hematology/The Education Program of the American Society of Hematology, vol. 2011, pp. 96–103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Theodorou, M. Speletas, A. Mamara et al., “Identification of a STAT5 target gene, Dpf3, provides novel insights in chronic lymphocytic leukemia,” PLoS ONE, vol. 8, no. 10, Article ID e76155, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Ghamlouch, H. Ouled-Haddou, G. Damaj, B. Royer, B. Gubler, and J.-P. Marolleau, “A combination of cytokines rescues highly purified leukemic CLL B-cells from spontaneous apoptosis in vitro,” PLoS ONE, vol. 8, no. 3, Article ID e60370, 2013. View at Publisher · View at Google Scholar · View at Scopus